News, Resources, Updates
A scientific hub to keep you informed about our latest research and company updates.
RENCA Mouse Mouse Model of Renal Cancer
Approximately 400,000 people are diagnosed with kidney cancer annually. Kidney tumors are classified into different subtypes based on the cell of origin. Over 85% of malignant renal cell tumors are RCC, with the other 15% being nephroblastic, mesenchymal and...
Introduction to InnoSer’s Preclinical Epilepsy Research CRO Platform
Preclinical epilepsy-related research with InnoSer Broadly speaking, epilepsy is a large spectrum of distinct epileptic syndromes that differ in their etiologies, mechanisms, pathophysiological processes, associated comorbidities, and response profile to available...
Phenotyping of a C3-PMP22 mouse model of CMT1A
Charcot-Marie Tooth (CMT) disease is a hereditary, demyelinating peripheral neuropathy, leading to progressive muscle atrophy, weakness and subsequent walking disabilities and sensory impairments. Charcot-Marie Tooth Type 1A (CMT1A) is the most common type of CMT,...
Glomerular filtration rate (GFR) in the ADPKD mouse model
Preclinical studies aiming to assess kidney function traditionally include readouts such as serum creatinine and/or blood urea nitrogen (BUN). However, the use of readouts that are more clinically relevant such as glomerular filtration rate (GFR) is highly encouraged,...
Characterization of a transgenic TDP-43 Mouse Model
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by progressive loss of upper and lower motoneurons. This leads to brain degeneration and muscle denervation, resulting in extensive muscle atrophy and functional motor impairments....
Effect of Salsalate on disease progression in the ADPKD Mouse Model
Salsalate is a pro-drug dimer of salicylate belonging to the family of NSAIDs, activating AMPK through direct interactions with the drug-binding domain of the AMPK beta-1 isoform. As such, Salsalate arises as a key candidate for drug repurposing in ADPKD. To...
info@innoserlaboratories.com